Enovis Corporation shares fall 1.53% premarket after launching Manafuse® bone growth stimulation.

Enovis Corporation fell 1.53% in premarket trading. The company recently launched Manafuse®, an advancement in bone growth stimulation, inspired by feedback from physicians and patients. This innovation, highlighted in a Q&A with Brad Batte, President of Enovis™ Regeneration, suggests a positive development for the company, which may not align with the stock's downward movement.